Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

251
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
251
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

111
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
111

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: A Multistate Retrospective Cohort Study.

Journal of medical Internet research·2026
Same author

ASAM Consensus Standards for Substance Use Disorder Care Capabilities in Hospitals and Emergency Departments.

Journal of addiction medicine·2026
Same author

Emergency Department-initiated standard versus high-dose buprenorphine induction (ENVISION): a randomised clinical trial protocol.

BMJ open·2026
Same author

GPEvidence.org: A Point-of-Care Resource for Primary Care.

American family physician·2026
Same author

Bone microarchitecture and material properties decline differently across midlife for male and female F344 × BN F1 rats.

bioRxiv : the preprint server for biology·2026
Same author

Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study.

Addiction science & clinical practice·2026

Related Experiment Video

Updated: Jun 14, 2025

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

315

Ketamine-assisted buprenorphine initiation: a pilot case series.

Lucinda A Grande1,2, Tom Hutch3,4, Keira Jack3

  • 1Pioneer Family Practice, 5130 Corporate Ctr Ct SE, Lacey, Washington, 98503, USA. cgrande@pioneerfamilypractice.com.

Addiction Science & Clinical Practice
|August 29, 2024
PubMed
Summary

Sublingual ketamine effectively reduced opioid withdrawal symptoms, enabling more patients to start buprenorphine treatment in an outpatient setting. This approach may lower barriers to essential addiction therapy.

Keywords:
Buprenorphine initiationFentanylKetamineMethadonePrecipitated withdrawal

More Related Videos

Engineered Vascularized Muscle Flap
08:18

Engineered Vascularized Muscle Flap

Published on: January 11, 2016

8.2K
A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
13:27

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat

Published on: October 6, 2018

8.1K

Related Experiment Videos

Last Updated: Jun 14, 2025

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

315
Engineered Vascularized Muscle Flap
08:18

Engineered Vascularized Muscle Flap

Published on: January 11, 2016

8.2K
A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
13:27

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat

Published on: October 6, 2018

8.1K

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Clinical Research

Background:

  • Opioid use disorder (OUD) treatment is hindered by fear of opioid withdrawal.
  • Buprenorphine initiation is often delayed due to concerns about spontaneous or buprenorphine-precipitated opioid withdrawal (BPOW).
  • Ketamine has shown potential in managing BPOW, but its use in outpatient settings requires careful dosing to avoid dissociative effects.

Purpose of the Study:

  • To explore the efficacy of low-dose, self-administered sublingual ketamine in facilitating buprenorphine initiation for ambulatory patients with OUD.
  • To assess ketamine's role in mitigating withdrawal symptoms during the transition from fentanyl or methadone to buprenorphine.

Main Methods:

  • Prescribed sublingual ketamine (16 mg per dose, 4-8 doses) to patients transitioning to buprenorphine who feared BPOW or were experiencing it.
  • Monitored patients daily or near-daily, adjusting ketamine and buprenorphine dosages based on response.
  • Included patients transitioning from illicit fentanyl and methadone.

Main Results:

  • Ketamine was prescribed to 37 patients; 16 (43%) completed buprenorphine initiation.
  • Of those who tried ketamine, 67% successfully initiated buprenorphine.
  • Most patients reported reduced or eliminated withdrawal symptoms; 92% of the last 12 completers had 30-day retention.
  • A protocol allowed four patients to initiate buprenorphine over four days with mild withdrawal.

Conclusions:

  • Sub-dissociative ketamine facilitated outpatient buprenorphine initiation for most patients who tried it.
  • Ketamine may reduce apprehension and lower barriers to buprenorphine treatment.
  • Further research is needed to confirm findings and develop standardized protocols for diverse settings.